Search

everythinglearnresearchcommunity

for

Search:↓

KRT80 may worsen cancer by increasing growth and spread, but its full effects on treatment and outcomes need more research.

Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.

Spironolactone does not increase the risk of breast cancer recurrence.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.

Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Hair loss is a common side effect of hormone treatments for cancer.

Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.

Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.

Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.

Cold Atmospheric Plasma shows promise in treating aggressive breast cancer by targeting cancer cells while sparing normal tissue.

Losing 5-10% body weight can improve PCOS symptoms, letrozole is better than clomiphene for fertility, and managing weight and blood sugar is important to reduce pregnancy complications.

Oral minoxidil effectively improves hair regrowth in cancer survivors with late alopecia.

A man with a rare adrenal cancer showed unusual symptoms and died four months after diagnosis.

Diagnosing and treating PCOS is complex due to differing criteria and requires a team approach.

Estrogen-progestin contraception lowers ovarian, endometrial, and colon cancer risk but may raise breast and cervical cancer risk, helps with menstrual and acne issues, and new methods are as effective as pills. Metformin helps overweight women with PCOS and insulin resistance, and dopamine agonists treat prolactinomas.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.

REV7 is crucial for genome stability and cancer treatment, making it a potential target for therapy.

Primary care is key in managing PCOS, focusing on lifestyle changes and medications like birth control and metformin.

Early diagnosis and treatment of PCOS is crucial to reduce emotional distress and health risks.